论文部分内容阅读
目的观察新辅助化疗后行保乳手术治疗非转移性乳腺癌的临床效果,探讨其临床价值,旨在为临床工作提供理论帮助。方法收集我院诊治的194例非转移性乳腺癌患者,随机分为观察组与对照组,观察组共102例,在新辅助化疗后行保乳手术治疗,术后进行规范治疗,对照组共92例,应用乳腺癌改良根治手术治疗,术后进行规范治疗,观察两组患者的美容效果及3年生存率,关注观察组化疗前后雌激素受体(ER)、孕激素受体(PR)的表达差别。结果观察组的美容效果明显,患者满意率高,观察组的3年生存率与对照组差距无统计学意义,观察组化疗前后ER、PR表达差别无统计学意义。结论新辅助化疗后行保乳手术治疗非转移性乳腺癌,临床美容效果明显,且能达到与根治手术相同的预后效果,对ER、PR无影响,临床中可以积极应用。
Objective To observe the clinical effect of breast-conserving surgery for non-metastatic breast cancer after neoadjuvant chemotherapy and to explore its clinical value, aiming to provide theoretical help for clinical work. Methods A total of 194 patients with non-metastatic breast cancer who were treated in our hospital were randomly divided into observation group and control group. The observation group consisted of 102 patients underwent conservative surgery after neoadjuvant chemotherapy, 92 patients were treated with modified radical mastectomy. Postoperative standard treatment was performed. The cosmetic effect and 3-year survival rate were observed in both groups. The estrogen receptor (ER), progesterone receptor (PR) The difference in expression. Results In the observation group, the cosmetic effect was obvious and the patient satisfaction rate was high. There was no significant difference in the 3-year survival rate between the observation group and the control group. There was no significant difference in ER and PR expression between the observation group before and after chemotherapy. Conclusions Neoadjuvant chemotherapy after breast conserving surgery in the treatment of non-metastatic breast cancer, clinical cosmetic effect is obvious, and can achieve the same prognosis and radical surgery effect, no effect on ER, PR, the clinical application can be positive.